Grand Greve Limited exits Celex Oncology Innovations cap table

Grand Greve Limited has exited the cap table of Celex Oncology Innovations Limited, according to the company's latest confirmation statement (covering the period to 5 April 2026). The entity previously held 22,075 Ordinary shares in the business. No new shareholders joined the register during this period, and no existing shareholders recorded an increase in their positions.

Based in London and founded in 2017, Celex Oncology Innovations Limited develops small-molecule therapies designed to target sodium overload in tumor cells. The company aims to rebalance cellular bioelectricity to reduce malignant progression and manage cancer as a chronic condition for oncology patients.

Several institutional and corporate investors remain on the cap table following this departure. NT Finance APS continues as a major shareholder with 584,523 shares, alongside Gemmabel Limited which holds 550,000 shares. Other significant holdings include 254,000 shares held by Celex Oncology Innovations Limited itself, 89,136 shares held by Floreat Investments Ltd, and 80,870 shares held by IQ EQ (Switzerland) Limited. Smaller stakes are maintained by Birchwood House Investments Limited and 8 KPG Ltd, which each hold 44,150 shares, and Neilsca Investments Limited with 33,531 shares.